Board Change • May 01
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Steve Picton was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Dec 24
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Steve Picton was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Annonce • Nov 25
Echo IQ Limited Completes its Clinical Validation for its Heart Failure Clinical Decision Support Software in Collaboration with the Mayo Clinic Platform Echo IQ Limited announced that it has completed its clinical validation for its heart failure clinical decision support software ("EchoSolv HF") in collaboration with the Mayo Clinic Platform ("MCP"), a division of the Mayo Clinic, a top ranked US hospital. The MCP Validate program is a unique in-market AI evaluation program which generates an independent and objective report on accuracy, efficacy and susceptibility to bias for AI-based decision software. The clinical validation was designed to evaluate the EchoSolv HF model's ability to detect heart failure on an independent dataset of ~17,000 individual echocardiogram studies. In a major milestone, the primary endpoint of the clinical validation has been met, with results exceeding expectations. The study results show that EchoSolv HF demonstrated outstanding performance in identifying patients with heart failure, achieving a sensitivity of 99.5%. Likewise, the model was accurate in identifying patient that did not have heart failure, achieving a specificity of 91.0%. Completion of the clinical validation marks the final clinical requirement prior to a formal submission for clearance by the US Food & Drug Administration ("FDA"). Echo IQ is now in the process of completing its formal submission to advance the clearance of EchoSolv HF via the FDA's 510(k) regulatory pathway. The Company expects to lodge this submission in the coming weeks. FDA clearance of the solution would allow for EchoSolv HF to be marketed to and used by healthcare professionals in the USA as a clinical decision support software to aid in the detection of heart failure. Heart failure is the leading cause for rehospitalisation in the US and accounts for 17% of all healthcare expenditure in the country. It is now estimated that one in four Americans will develop heart failure in their lifetime. Upon potential FDA clearance of the solution, the Company intends to leverage its existing footprint in the US market to drive uptake of EchoSolv HF. Annonce • Nov 13
Echo Iq Highlights Market Potential for Echosolv as Following Presentation of New Data for Severe Aortic Stenosis (As) Presented At Aha Scientific Sessions 2025 Echo IQ announced that overwhelmingly convincing data from two recent studies have highlighted the significant gaps in the current standard-of-care for diagnosing and monitoring severe aortic stenosis (AS), and potential for EchoSolv AS to drive improved patient outcomes. The results from both studies were presented separately at the American Heart Association (AHA) Scientific Sessions 2025, which was held in New Orleans, Louisiana. A key takeaway from the study that reviewed echocardiograms for more than 1.2 million patients is that the 'watchful waiting' strategy for moderate-to-severe AS cases is failing many of these patients. In addition, the insights from the results that show how EchoSolv AS was able to identify the severe AS phenotype more accurately than cardiologists, particularly in some subtypes of AS. This study was of particular interest as it showed clearly that the company have work to do in accurately diagnosing women with aortic stenosis and the company are optimistic with the performance of EchoSolv AS to improve the gender equity. Study titled, "Accuracy of cardiologist reporting of severe aortic stenosis vs decision-support artificial intelligence and its impact on clinical management" presented by Dr. Vikas Bhat, University of Notre Dame Australia, this investigator-initiated study compared traditional cardiologist reporting with EchoSolv™?, an AI-powered clinical decision support system. Findings from 30,878 echocardiograms revealed: EchoSolv outperformed cardiologists in identifying severe AS phenotypes, particularly in women and low- gradient cases. Findings underscore the need for policy and clinical practice changes to address treatment gaps and improve survival. This study was funded by an IIS grant from Edwards LifeScience. The funders played no part in the data curation/analysis /preparation of these data. EchoSolv AS is poised to change this paradigm by enabling more precise and consistent identification of high-risk AS patients, thereby supporting clinicians in making informed, timely decisions regarding intervention. Globally, AS is a widespread but frequently underdiagnosed condition, primarily caused by calcification of the aortic valve, which serves as a critical gateway to the heart. Failure to diagnose AS in a timely manner can lead to missed opportunities for lifesaving interventions, such as valve replacement surgery. EchoSolv AS has undergone rigorous validation, including FDA Clearance, through extensive testing across both the United States and Australia, demonstrating the utility of aiding in the accurate diagnosis of patients with aortic stenosis. NEDA principal investigator, Professor David Playford, the senior author for both studies, said: " These studies confirm previous reports in two ways. First, reaffirm that moderate and severe aortic stenosis is a lifethreatening condition that causes significant health service utilization, heart failure hospitalizations and premium mortality. Second, artificial intelligence is capable of outperforming cardiologists in the identification of the set of abnormalities that happen when aortic stenosis progresses toward the severe state. These two findings, taken together, reinforce that EchoSolv AS AI should be considered as a routine option during echocardiographic reporting. Authorised for release by the Board of Directors of Echo IQ Limited. Annonce • Sep 30
Echo IQ Limited, Annual General Meeting, Nov 18, 2025 Echo IQ Limited, Annual General Meeting, Nov 18, 2025. Breakeven Date Change • Aug 31
Forecast breakeven date pushed back to 2027 The 2 analysts covering Echo IQ previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 83% to 2026. The company is expected to make a profit of AU$44.4m in 2027. Average annual earnings growth of 51% is required to achieve expected profit on schedule. Board Change • Aug 18
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Steve Picton was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Annonce • May 07
Echo IQ Limited has completed a Follow-on Equity Offering in the amount of AUD 17.3 million. Echo IQ Limited has completed a Follow-on Equity Offering in the amount of AUD 17.3 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 56,666,667
Price\Range: AUD 0.3
Discount Per Security: AUD 0.018
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,000,000
Price\Range: AUD 0.3
Discount Per Security: AUD 0.018
Transaction Features: Subsequent Direct Listing Annonce • Apr 03
Echo IQ Provides Update on the Company's Pre-Submission Meeting with the United States Food and Drug Administration Regarding Its Heart Failure Clinical Decision Support Solution Echo IQ provided an update on the Company's pre-submission meeting with the United States ("US") Food and Drug Administration ("FDA") regarding its heart failure clinical decision support solution ("EchoSolv HF"). The Company is also pleased to announceda collaboration agreement with the Mayo Clinic Platform, part of the Mayo Clinic, a top-ranked US hospital, to undertake Echo IQ's proposed validation study and qualify the Company's artificial intelligence ("AI") heart failure model. The study, expected to commence this quarter, marks the final clinical requirement prior to a formal submission for clearance by the FDA. Echo IQ anticipates FDA clearance for EchoSolv HF during H2 CY2025. Echo IQ requested the pre-submission meeting with the US FDA in December 2024 to verify the design for a proposed validation study which will evaluate EchoSolv HF in its ability to detect various forms of heart failure. The Company undertook the meeting during the first quarter of 2025 and advises that it had positive engagement with the regulator. The engagement has provided the Company confidence to advance the proposed study design of EchoSolv HF's upcoming clinical validation study. Agreement with the Mayo Clinic Platform to undertake validation study and utilisation of EchoSolv HF: Following the pre-submission meeting, the Company executed a collaboration agreement with the Mayo Clinic Platform to undertake the upcoming validation study. Mayo Clinic Platform is focused on earlier diagnoses, more accurate diagnosis and care personalised for each person. Mayo Clinic Platform is creating a world where the best possible care is available to everyone, everywhere. As new technologies create novel opportunities and approaches, Mayo Clinic Platform is harnessing these new technologies to change how care is provided. As part of the agreement, the Mayo Clinic Platform also has the right to utilise EchoSolv HF within the group's network of 30 hospitals, utilise Mayo Clinic Platform's proprietary integration software system alongside the product and co-brand with the Company on its EchoSolv HF and heart failure related materials. The pending validation study will commence this quarter with anticipated completion mid-year. This leaves the Company well placed to meet its proposed timelines for a formal submission to the FDA for regulatory clearance of EchoSolv HF in H2 this calendar year. The agreement with Mayo Clinic Platform provides strong validation of the Company's offering and its potential to positively impact heart failure, which is a widespread condition globally. Heart failure is the leading cause of re-hospitalisation in the US, accounting for 17% of all US healthcare expenditure i. The market for heart failure is estimated to be USD 70 billion annually ii. Board Change • Feb 04
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Steve Picton was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Dec 24
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Steve Picton was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Annonce • Dec 12
Echo IQ Limited Appoints Ken Nelson A Non-Executive Director Echo IQ Limited advised that US-based healthcare and medical technology executive Mr. Ken Nelson has been appointed a Non-Executive Director, effective 11 December 2024. In line with Mr. Nelson's appointment, Mr. Simon Tolhurst has tendered his resignation from the Board of Directors. Mr. Tolhurst has been a member of the Company's Board since June 2023 and has provided exceptional guidance on Echo IQ's growth trajectory to date, where his specialist expertise was highly valued as part of the Company's successful FDA Clearance. Incoming Director, Mr. Ken Nelson is a leading US-based medical technology and healthcare executive with over 20 years' industry experience. During his career he has been pivotal in leading successful commercialisation efforts with multiple cardiac-focused digital health companies including remote cardiac and diagnostics monitoring business, BioTelemetry, wearable device company, iRhythm and ambulatory ECG solutions monitoring group, Bardy Diagnostics. Currently, he serves as partner in the Medtech Advantage Fund, which has an exclusive partnership with Medtech Innovator. In addition to this, Mr. Nelson serves as Chairman to the Board of Israeli-based medical technology company, CardiaCare, and is an active Board member of other cardiac-focused digital health and medical technology companies including HeartBeam, Acarix, US-based company Epitel, and European-based platform Happitech. Mr. Nelson also sits on a number of advisory boards and planning committees for early-stage medical technology companies, as well as several industry groups including the Innovation Advisory Board of Heart Rhythm Society, the Health Tech Innovation Business Advisory Board and the Heart & Brain Accelerator of the American Heart Association. Mr. Nelson has an extensive network in the global medical technology sector and strong relationships with a large cohort of sophisticated investors in the healthcare sector. The Company is confident that his expansive network will be beneficial as Echo IQ continues to execute its commercialisation strategy. Annonce • Oct 09
Echo IQ Limited Announces CEO Changes, Effective 10 January 2025 Echo IQ Limited that senior healthcare executive, Mr. Dustin Haines, has been appointed as Chief Executive Officer, effective 10 January 2025 and will be based in the US to spearhead the Company's strategy. Mr. Haines has exceptional experience, stemming from a 25-year career in the biotechnology and pharmaceutical sectors. As CEO, Mr. Haines will be focused on executing the Company's stated growth strategy starting with commercialization in the US market, which will include obtaining relevant market access and reimbursement of the Company's technology. Mr. Haines has extensive experience with building high performing teams and bringing innovation to the market. His knowledge of the industry is expected to play an important role in the Company's strategy. As previously advised, Echo IQ is in advanced negotiations with multiple large hospital groups, pharmaceutical companies and device manufacturers around the uptake of EchoSolv and is confident Mr. Haines' skillset will assist with executing on these negotiations to grow revenue. Echo IQ also plans to leverage Mr. Haines' extensive network to further broaden its pipeline of opportunities in the US and internationally. Mr. Haines, a US citizen and seasoned American healthcare executive, was most recently Vice President & General Manager of Gilead Sciences, Asia, Middle East, Turkey and Russia. During this time, he led business development across several product categories including infectious disease, oncology and immunology. Prior to his time at Gilead Sciences, he was Chief Commercial Officer at medical technology company, Next Science Limited. Mr. Haines has also spent over a decade in senior roles with both ViiV Healthcare and GSK (GlasxoSmithKline), where he was instrumental in delivering Phase 3 assets through to category leading commercialization. In these roles, Mr. Haines covered Japan, Europe and the US, where he has developed extensive networks. Upon commencement of Mr. Haine's tenure, Mr. Andrew Grover will relinquish the role of interim Managing Director and maintain his role as Executive Chair. Reported Earnings • Oct 05
Full year 2024 earnings released: AU$0.011 loss per share (vs AU$0.018 loss in FY 2023) Full year 2024 results: AU$0.011 loss per share (improved from AU$0.018 loss in FY 2023). Net loss: AU$5.41m (loss narrowed 35% from FY 2023). Annonce • Sep 24
Echo IQ Limited, Annual General Meeting, Nov 12, 2024 Echo IQ Limited, Annual General Meeting, Nov 12, 2024. Reported Earnings • Aug 30
Full year 2024 earnings released: AU$0.012 loss per share (vs AU$0.018 loss in FY 2023) Full year 2024 results: AU$0.012 loss per share (improved from AU$0.018 loss in FY 2023). Net loss: AU$5.41m (loss narrowed 35% from FY 2023). New Risk • Mar 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.8m free cash flow). Earnings have declined by 39% per year over the past 5 years. Revenue is less than US$1m (AU$782k revenue, or US$511k). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (8.5% increase in shares outstanding). Market cap is less than US$100m (AU$66.8m market cap, or US$43.7m). Annonce • Feb 01
Echo IQ Limited Announces the Resignation of Shannon Robinson from the Role of Joint Company Secretary Echo IQ Limited advised that Shannon Robinson has resigned from the role of Joint Company Secretary. Jessamyn Lyons remains in the role of Company Secretary to the Company and its subsidiaries. Annonce • Oct 05
Echo IQ Limited, Annual General Meeting, Nov 21, 2023 Echo IQ Limited, Annual General Meeting, Nov 21, 2023. Reported Earnings • Oct 02
Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.017 loss in FY 2022) Full year 2023 results: AU$0.018 loss per share (further deteriorated from AU$0.017 loss in FY 2022). Net loss: AU$8.27m (loss widened 27% from FY 2022). Reported Earnings • Sep 01
Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.017 loss in FY 2022) Full year 2023 results: AU$0.018 loss per share (further deteriorated from AU$0.017 loss in FY 2022). Net loss: AU$8.21m (loss widened 27% from FY 2022). New Risk • Aug 31
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.1m free cash flow). Earnings have declined by 37% per year over the past 5 years. Revenue is less than US$1m (AU$156k revenue, or US$101k). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (15% increase in shares outstanding). Significant insider selling over the past 3 months (AU$92k sold). Market cap is less than US$100m (AU$74.0m market cap, or US$47.9m). Annonce • Jun 03
Echo IQ Announces the Appointment of Simon Tolhurst as A Non-Executive Director Echo IQ announced the appointment of Simon Tolhurst as a Non-Executive Director, effective from 1 June 2023. Mr. Tolhurst brings extensive board experience to the role. For five years, he was Non-Executive Chairman of ASX-listed NextEd Group Ltd. where he oversaw a period of significant growth, a company transformational acquisition matched with share price appreciation. He continues to serve as a Non-Executive Director at NextED Group Ltd. and holds other senior board roles in the private sector. Simon has more than 30 years' experience in legal practice, and was until recently a Partner at HWL Ebsworth's Litigation Team prior to his recent retirement as a practicing lawyer. His areas of expertise include dispute resolution and competition law. He was named in The Australian Financial Review's Best Lawyers® in the Litigation category, was recognised in Doyle's Guide as a Leading Commercial Litigation & Dispute Resolution Lawyer and was part of the HWL Ebsworth's National Competition Law and Anti-Trust Group that was recognised as a leading firm by both Chambers and Legal 500. Reported Earnings • Mar 03
First half 2023 earnings released: AU$0.01 loss per share (vs AU$0.009 loss in 1H 2022) First half 2023 results: AU$0.01 loss per share (further deteriorated from AU$0.009 loss in 1H 2022). Net loss: AU$4.61m (loss widened 31% from 1H 2022). Board Change • Nov 17
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Chairman Steve Formica was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 02
Full year 2022 earnings released: AU$0.016 loss per share (vs AU$0.011 loss in FY 2021) Full year 2022 results: AU$0.016 loss per share (down from AU$0.011 loss in FY 2021). Revenue: AU$836.5k (down 15% from FY 2021). Net loss: AU$6.17m (loss widened 106% from FY 2021). Board Change • Apr 28
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Non-Executive Director Steve Formica is the most experienced director on the board, commencing their role in 2018. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Board Change • Jan 12
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Non-Executive Director Steve Formica is the most experienced director on the board, commencing their role in 2018. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.